Effect of interactions between C peptide levels and insulin treatment on clinical outcomes among patients with type 2 diabetes mellitus

Ko, Gary T.C.; So, Wing-Yee; Tong, Peter C.; Chan, Wing-Bun; Xilin Yang; Ma, Ronald C.; Kong, Alice P.; Ozaki, Risa; Yeung, Chun-Yip; Chow, Chun-Chung; Chan, Juliana C.
April 2009
CMAJ: Canadian Medical Association Journal;4/28/2009, Vol. 180 Issue 9, p919
Academic Journal
Background: A recently halted clinical trial showed that intensive treatment of type 2 diabetes mellitus was associated with increased mortality. Given the phenotypic heterogeneity of diabetes, therapy targeted at insulin status may maximize benefits and minimize harm. Methods: In this longitudinal cohort study, we followed 503 patients with type 2 diabetes who were free of cardiovascular disease from 1996 until data on mortality and cardiovascular outcomes were censored in 2005. Phenotype-targeted therapy was defined as use of insulin therapy in patients with a fasting plasma C peptide level of 0.2 nmol/L or less and no insulin therapy in patients with higher C peptide levels. Results: The mean age of the cohort was 54.4 (standard deviation 13.1) years, and 56% were women. The mean duration of diabetes was 4.6 years (range 0-35.9 years). Of the 503 patients, 110 (21.9%) had a low C peptide level and 111 (22.1%) were given insulin. Based on their C peptide status, 338 patients (67.2%) received phenotype-targeted therapy (non-insulin-treated, high C peptide level [n = 310] or insulin-treated, low C peptide level [n = 28]), and 165 patients (32.8%) received non-phenotype-targeted therapy (non-insulin-treated, low C peptide level [n = 82] or insulintreated, high C peptide level [n = 83]). Compared with the insulin-treated, low-C-peptide referent group, the insulintreated, high-C-peptide group was at a significantly higher risk of cardiovascular events (hazard ratio [HR] 2.85, p = 0.049) and death (HR 3.43, p = 0.043); the risk was not significantly higher in the other 2 groups. These differences were no longer significant after adjusting for age, sex and diabetes duration. Interpretation: Patients with low C peptide levels who received insulin had the best clinical outcomes. Patients with normal to high C peptide levels who received insulin had the worst clinical outcomes. The results suggest that phenotype-targeted insulin therapy may be important in treating diabetes.


Related Articles

  • Immunomodulatory therapy to preserve pancreatic β-cell function in type 1 diabetes. Waldron-Lynch, Frank; Herold, Kevan C. // Nature Reviews Drug Discovery;Jun2011, Vol. 10 Issue 6, p439 

    Type 1 diabetes is a common, severe chronic autoimmune disease that is characterized by the progressive and insidious loss of self-tolerance to the insulin-producing pancreatic islet β-cells. This loss of self-tolerance leads to the destruction of β-cells and the development of overt...

  • Islet Transplantation Is Associated With an Improvement of Cardiovascular Function in Type 1 Diabetic Kidney Transplant Patients. Fiorina, Paolo; Gremizzi, Chiara; Maffi, Paola; Caldara, Rossana; Tavano, Davide; Monti, Lucilla; Socci, Carlo; Folli, Franco; Fazio, Ferruccio; Astorri, Ettore; Del Maschio, Alessandro; Secchi, Antonio // Diabetes Care;Jun2005, Vol. 28 Issue 6, p1358 

    OBJECTIVE -- Cardiovascular mortality and morbidity are major problems in type 1 diabetic patients with end-stage renal disease (ESRD). The aim of this study was to determine whether islet transplantation can improve cardiovascular function in these patients. RESEARCH DESIGN AND METHODS -- We...

  • Minimal Functional β-CellMass in Intraportal Implants That Reduces Glycemic Variability in Type 1 Diabetic Recipients. GILLARD, PIETER; HILBRANDS, ROBERT; VAN DE VELDE, URSULE; ZHIDONG LING; DA HAE LEE; WEETS, ILSE; GORUS, FRANS; DE BLOCK, CHRISTOPHE; KAUFMAN, LEONARD; MATHIEU, CHANTAL; PIPELEERS, DANIEL; KEYMEULEN, BART // Diabetes Care;Nov2013, Vol. 36 Issue 11, p3483 

    OBJECTIVE-Previous work has shown a correlation between b-cell number in cultured islet cell grafts and their ability to induce C-peptide secretion after intraportal implantation in C-peptide-negative type1 diabetic patients. In this cross-sectional study, we examined the minimal functional...

  • B-Cells Promote Intra-Islet CD8+ Cytotoxic T-Cell Survival to Enhance Type 1 Diabetes. Brodie, Gillian M.; Wallberg, Maja; Santamaria, Pere; Wong, F. Susan; Green, E. Allison // Diabetes;Apr2008, Vol. 57 Issue 4, p909 

    OBJECTIVE--To determine the role of B-cells in promoting CD8[sup +] T-cell--mediated β cell destruction in chronically inflamed islets. RESEARCH DESIGN AND METHODS--RIP-TNFα-NOD mice were crossed to B-cell-deficient NOD mice, and diabetes development was monitored. We used in vitro...

  • Microencapsulated Pancreatic Islet Allografts Into Nonimmunosuppressed Patients With Type 1 Diabetes. Calafiore, Riccardo; Basta, Giuseppe; Luca, Giovanni; Lemmi, Angelo; Montanucci, M. Pia; Calabrese, Giuseppe; Racanicchi, Leda; Mancuso, Francesca; Brunetti, Paolo // Diabetes Care;Jan2006, Vol. 29 Issue 1, p137 

    The article presents information on a phase 1 pilot clinical trial of microencapsulated pancreatic islet allograft into 10 nonimmunsuppressed patients with type 1 diabetes, under permission and surveillance by the Italian Ministry of Health. Research design and methods are given. Results and...

  • Gastrointestinal hormones and the regulation of �-cell mass. Lavine, Jeremy A.; Attie, Alan D. // Journal of Dental Hygiene;Fall2011, Vol. 85 Issue 4, p41 

    Type 2 diabetes occurs due to a relative deficit in �-cell mass or function. Glucagon-like peptide 1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), cholecystokinin (CCK), and gastrin are gastrointestinal hormones that are secreted in response to nutrient intake, regulating...

  • Impact of Islet Transplantation on Cardiovascular Disease Progression. Hatipoglu, Betul; Uy, Arleen; Naing, Soe; Martellotto, Joan; Barbaro, Barbara; Salehi, Payam; Gangemi, Antonio; Kuechle, Joseph; Benedetti, Enrico; Kaplan, Bruce; Oberholzer, Jose // Diabetes;Jun2007 Supplement 1, Vol. 56, pA179 

    Cardiovascular disease is highly prevalent in diabetic patients. Inflammation and dyslipidemia play an important role in diabetic atherogenesis, likely related to chronic hyperglycemia. We examined the effect of islet transplantation and immunsuppression on inflammation and lipid profiles, as...

  • Where Do We Stand With INGAP? Vinik, Aaron I. // Diabetes Health;Jun2004, Vol. 13 Issue 6, p72 

    Interviews physician Aaron I. Vinik, research director for the Strelitz Diabetes Institutes at Eastern Virginia Medical School and one of the discoverer of the islet neogenesis associated protein (INGAP). Significance of the phase 2 trials; Results obtained in phase 1B; Role of INGAP in insulin...

  • Sernova Breaks New Ground In Islet Cell Transplantation. Shaffer, Catherine // BioWorld Today;8/17/2012, Vol. 23 Issue 160, p1 

    The article reports on the Phase I/II trial conducted by Sernova Corp. involving patients with type I diabetes which combines transplanted insulin-producing islet cells with its Cell Pouch device. A total of 5 million dollars has been raised by the company to finance the test which is expected...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics